Press Releases

Date	Title
May 12, 2021	Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021 Live video webcast with Outlook Therapeutics’ management team and key opinion leaders on Thursday, May 20th from 11:00 AM – 1:00 PM ET ISELIN, N.J. , May 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the
March 31, 2021	Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Positive safety profile in NORSE THREE open-label safety study reinforces previously reported safety data for ONS-5010 / LYTENAVA™ , an investigational ophthalmic formulation of bevacizumab-vikg for the treatment of wet AMD Topline efficacy and safety data from pivotal Phase 3 NORSE TWO study on
March 4, 2021	Outlook Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference MONMOUTH JUNCTION, N.J. , March 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
February 17, 2021	Outlook Therapeutics to Participate in Cantor Fitzgerald’s Virtual Panel Discussion: Eyeing Key Events and Programs in the Ophthalmology Space in 2021 MONMOUTH JUNCTION, N.J. , Feb. 17, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today announced that Lawrence
February 16, 2021	Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update Topline data from pivotal Phase 3 safety and efficacy study (NORSE TWO) on target to report in Q3 2021 Topline data from the open-label safety study (NORSE THREE) on target to report in Q2 2021 Recent funding significantly enhances financial position, extends cash runway through BLA filing and
February 11, 2021	Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg) Topline results from open-label safety study (NORSE THREE) on target for Q2 2021 MONMOUTH JUNCTION, N.J. , Feb. 11, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of
February 4, 2021	Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission Overallotment option on recent public offering partially exercised by underwriter Closed concurrent private placement for $3.0 million gross proceeds Aggregate gross proceeds of $41.6 million strengthens financial position and provides strategic optionality to maximize stockholder value MONMOUTH
February 2, 2021	Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal MONMOUTH JUNCTION, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today
January 28, 2021	Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications,
January 28, 2021	Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock MONMOUTH JUNCTION, N.J. , Jan. 28, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, today